skip to main content
Idioma:

Retracted: Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data

Hirth, Jacqueline M. ; Hatch, Sandra S. ; Lin, Yu‐Li ; Giordano, Sharon H. ; Silva, H. Colleen ; Kuo, Yong‐Fang

Cancer, 2018-07, Vol.124 (13), p.2815-2823 [Periódico revisado por pares]

Atlanta: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
  • Título:
    Retracted: Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data
  • Autor: Hirth, Jacqueline M. ; Hatch, Sandra S. ; Lin, Yu‐Li ; Giordano, Sharon H. ; Silva, H. Colleen ; Kuo, Yong‐Fang
  • Assuntos: administrative claims data ; algorithm performance ; breast cancer ; ductal carcinoma in situ (DCIS) ; validation
  • É parte de: Cancer, 2018-07, Vol.124 (13), p.2815-2823
  • Notas: Preliminary data from this study were presented at the National Comprehensive Cancer Network (NCCN) 22nd Annual Conference: Advancing the Standard of Cancer Care General Poster Session; March 23‐25, 2017; Orlando, FL.
  • Descrição: Background Overtreatment is a common concern for patients with ductal carcinoma in situ (DCIS), but this entity is difficult to distinguish from invasive breast cancers in administrative claims data sets because DCIS often is coded as invasive breast cancer. Therefore, the authors developed and validated algorithms to select DCIS cases from administrative claims data to enable outcomes research in this type of data. Methods This retrospective cohort using invasive breast cancer and DCIS cases included women aged 66 to 70 years in the 2004 through 2011 Texas Cancer Registry (TCR) data linked to Medicare administrative claims data. TCR records were used as “gold” standards to evaluate the sensitivity, specificity, and positive predictive value (PPV) of 2 algorithms. Women with a biopsy enrolled in Medicare parts A and B at 12 months before and 6 months after their first biopsy without a second incident diagnosis of DCIS or invasive breast cancer within 12 months in the TCR were included. Women in 2010 Medicare data were selected to test the algorithms in a general sample. Results In the TCR data set, a total of 6907 cases met inclusion criteria, with 1244 DCIS cases. The first algorithm had a sensitivity of 79%, a specificity of 89%, and a PPV of 62%. The second algorithm had a sensitivity of 50%, a specificity of 97%. and a PPV of 77%. Among women in the general sample, the specificity was high and the sensitivity was similar for both algorithms. However, the PPV was approximately 6% to 7% lower. Conclusions DCIS frequently is miscoded as invasive breast cancer, and thus the proposed algorithms are useful to examine DCIS outcomes using data sets not linked to cancer registries. Cancer 2018;124:2815‐2823. © 2018 American Cancer Society Cases of ductal carcinoma in situ (DCIS) often are inaccurately coded as invasive breast cancer in medical administrative claims data. In an assessment of 2 algorithms to select true cases of DCIS from an administrative claims data set, the authors report on 1 algorithm that would be useful for the examination of DCIS incidence in a population, and a second algorithm that would be useful for examining outcomes related to treatment.
  • Editor: Atlanta: Wiley Subscription Services, Inc
  • Idioma: Inglês
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.